Grail
More than 400 sufferers who signed as much as take a pioneering oncology detection check developed by US biotech firm Grail obtained faulty letters final month suggesting they might have developed most cancers.
According to an inner firm doc seen by the Financial Times, 408 sufferers had been incorrectly advised that they had a sign of their blood suggesting they might have most cancers.
Grail mentioned the letters had been despatched “in error” by its telemedicine supplier PWNHealth and that its workers had moved swiftly to contact affected clients to reassure them their check outcomes had been improper.
The incident has generated concern amongst some insurers who’re trialing Galleri, a multi-cancer early detection check that claims to have the ability to spot greater than 50 cancers from a single draw of blood.
MassMutual, one of many greatest US life assurers, mentioned a “small number” of its policyholders had been affected and that it had “paused” its pilot because of this.
“We are aware that Grail proactively reached out to all our participants to address this issue as quickly as possible,” it mentioned.
Principal, one other huge US life assurer that has clients affected by the error, mentioned it was reviewing its relationship with Grail following the incident.
The episode underlines the dangers for insurers in adopting early-detection applied sciences, which supply the prospect of decreasing the quantity paid out in claims by retaining clients more healthy.
Grail, which is a subsidiary of the world’s greatest gene sequencing firm Illumina, is promoting Galleri at about $950 per check and advertising it to insurers and enormous employers. The check scans so-called cell-free DNA for adjustments brought on by most cancers cells.
The check has been hailed as “revolutionary” and “cutting edge” by British and US well being chiefs, though many specialists have urged warning in introducing them earlier than large-scale scientific trials show they’ll save lives.
Grail mentioned the faulty letters had been by no means associated to or brought on by an incorrect Galleri laboratory check end result. The letters had been inadvertently triggered by a PWNHealth software program configuration subject, which had now been disabled, it mentioned in an announcement.
PWNHealth mentioned it had promptly launched an investigation and addressed the underlying drawback inside an hour of turning into conscious of it and that it had carried out processes to make sure it didn’t occur once more.
“In partnership with Grail, we started contacting impacted individuals within 36 hours,” it added.
Grail, which is because of make a presentation on Galleri this weekend on the greatest most cancers convention within the US, mentioned greater than half of people who obtained the letters had not but had their blood drawn for the Galleri check.
“No patient health information has been disclosed or breached due to this issue, and no patient harm or adverse events have been reported,” the corporate mentioned.
In February, US life insurance coverage firm John Hancock introduced it might increase entry to Grail’s “first-of-a-kind” check, saying preventive care and early detection was vital to its dedication to assist clients stay “longer, healthier, better lives.” It collaborated with Munich Re on the pilot introduced in September.
A spokesperson for John Hancock mentioned its partnership with Grail had not modified. Munich Re declined to remark.
PWNHealth, which is a subsidiary of Everlywell, a digital well being firm, is an unbiased telemedicine vendor which evaluations Galleri check requests, prescribes the check and delivers outcomes to sufferers.
© 2023 The Financial Times Ltd. All rights reserved. Not to be redistributed, copied, or modified in any method.